Lv1
50 积分 2025-09-07 加入
Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1
18天前
已完结
Design, Synthesis and Evaluation of Thioacetamide‐Tethered Thiadiazole‐1,2,4‐Triazole Hybrids as SHP2 Inhibitors for Cancer Therapy
3个月前
已完结
A patent review of SHP2 allosteric inhibitors (2018-present)
3个月前
已完结
Abstract LB050: Modulation of innate and adaptive immunity in blood and tumor of patients receiving the SHP2 inhibitor RMC-4630
3个月前
已关闭
The principles of neoplasia and oncology
5个月前
已完结
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
5个月前
已完结
JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
5个月前
已完结
Abstract 4012: Preclinical development of SHP2 allosteric inhibitor ICP-189
5个月前
已关闭
Development of Clinically Viable Non-Muscle Myosin II Small Molecule Inhibitors with Broad Therapeutic Potential
8个月前
已完结
Development of clinically viable non-muscle myosin II small molecule inhibitors
8个月前
已完结
皖公网安备34019202002308
